June 24, 2020 / 11:48 AM / 15 days ago

Fulcrum Therapeutics begins trial of muscle disorder drug for COVID-19 patients

(Reuters) - Fulcrum Therapeutics Inc said on Wednesday it has started the late-stage trial of its experimental muscle disorder drug, losmapimod, in high-risk hospitalized adults that tested positive for COVID-19.

The company expects to report topline data in the first quarter of 2021.

Fulcrum said it had exclusively in-licensed losmapimod from GlaxoSmithKline PLC last year.

Reporting By Mrinalika Roy in Bengaluru, Editing by Sherry Jacob-Phillips

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below